Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

Phase : Phase III Indication : Erectile Dysfunction Study Design : open-label, fixed dose, 6-month extension study (parent study : DA8159_EDD_III)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A Pharmaceutical Co., Ltd.
• Treatments: Udenafil

Criteria

Inclusion Criteria:

• Male patients aged 20 years or more diagnosed with erectile dysfunction(ED)

Exclusion Criteria:

• Had uncontrolled blood pressure

• Had hepatic or renal dysfunction

• Had significant psychiatric disorders or drug abuses

• Was currently under anticancer chemotherapy

• Had a treatments for ED using other phosphodiesterase type 5(PDE-5) inhibitors